Biodesix (NASDAQ:BDSX) Issues Quarterly Earnings Results, Hits Expectations

Posted by on Nov 6th, 2026

Biodesix (NASDAQ:BDSX – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75), FiscalAI reports. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The firm had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.49 million.

Here are the key takeaways from Biodesix’s conference call:

  • Biodesix reported Q3 revenue of $24.0 million, up 10%, and diagnostic test volume up 24%, but results fell short of expectations. Management attributed the shortfall to fewer sales representatives than planned, weaker-than-expected primary-care seasonality and delayed development-services projects.
  • The company lowered its 2026 revenue outlook to $101 million–$103 million, or about 15% growth at the midpoint. Management expects development-services revenue to remain near $1 million in Q4, with many projects shifting into 2027; it also said a higher mix of Nodify CDT tests is weighing on average revenue per test.
  • Commercial capacity has improved to about 110 representatives, with a target of 115 by year-end. Management said October was its strongest month of new-physician acquisition this year and expects added sales capacity and improved forecasting to support a recovery, while noting new hires take time to ramp.
  • Biodesix cited the CHEST lung-nodule management framework and early enterprise-wide integrations at two major health systems as support for broader use of its Nodify tests. These system-level rollouts could make adoption more scalable, though management cautioned that implementation takes time.
  • The company is expanding beyond blood-based diagnostics with a radiomic lung-nodule test targeted for commercialization in 2028 and two MRD assay programs developed with Bio-Rad and Thermo Fisher. These initiatives broaden its longer-term opportunity, but remain in development.

Biodesix Stock Performance

Shares of NASDAQ BDSX traded down $1.65 during mid-day trading on Thursday, hitting $19.84. The company had a trading volume of 185,258 shares, compared to its average volume of 78,704. Biodesix has a 12 month low of $5.26 and a 12 month high of $31.97. The stock has a market cap of $209.33 million, a price-to-earnings ratio of -6.26 and a beta of 0.65. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85. The firm’s 50 day simple moving average is $25.93 and its two-hundred day simple moving average is $18.90.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BDSX. Canaccord Genuity Group boosted their target price on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating on shares of Biodesix in a research report on Thursday, October 22nd. Finally, TD Cowen reiterated a “buy” rating and issued a $40.00 price target (up from $30.00) on shares of Biodesix in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.25.

Read Our Latest Stock Analysis on BDSX

Insider Buying and Selling

In related news, Director Jack Schuler bought 15,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were purchased at an average cost of $24.47 per share, with a total value of $367,050.00. Following the completion of the transaction, the director directly owned 555,810 shares of the company’s stock, valued at approximately $13,600,670.70. This represents a 2.77% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders acquired 42,600 shares of company stock worth $1,033,062. 23.20% of the stock is owned by corporate insiders.

Biodesix Company Profile

(Get Free Report)

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.

Read More

Earnings History for Biodesix (NASDAQ:BDSX)

Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.